A Study of ERAS-601 in People With Chordoma

• Age ≥ 18 years.
• Have histologically confirmed chordoma that is not dedifferentiated or poorly differentiated subtype.
• Have progressive disease per RECIST 1.1 defined by +20% change between any two scans in the 9 months prior to enrollment.
• Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
• Recovered from acute, clinically significant toxicities associated with current/recent treatments to acceptable baseline status

• Screening laboratory values must meet the following criteria and should be obtained within 30 days prior to study treatment:

  • Absolute neutrophil count (ANC) ≥ 1.5 x 103/m
  • Platelet count ≥ 75 × 103/mL without symptomatic bleeding
  • Hemoglobin > 9 g/dL
  • Serum electrolytes (sodium, potassium, magnesium, phosphorus, calcium) Grade ≤1 or within the institutional ranges of normal. If clinically appropriate, electrolytes may be corrected, and values reassessed prior to enrollment.
  • AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases
  • Total bilirubin ≤ 1.5 × ULN (except in patients with Gilbert Syndrome who can have total bilirubin \< 3.0 mg/dL)
  • Serum creatinine clearance \<1.5 times ULN or ≥ 50 mL/min as determined by Cockcroft-Gault (Appendix 7) (creatinine clearance need not be calculated if serum creatinine is within normal limits).

Female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within 7 days prior to receiving the first dose of study medication.

• Female patients of childbearing potential must be willing to use an adequate method of contraception, as outlined in the protocol, for the course of the study through 120 days after last dose of study medication.
• Male patients of childbearing potential must agree to use an adequate method of contraception, as outlined in the protocol, starting with the first dose of study therapy through 120 days after the last dose of study therapy.
• Willing to comply with all protocol required- visits, assessments, and procedures.
• Willing to participate in patient interviews for quality-of-life assessment and complete patient reported outcomes (PRO) questionnaires
• Non-English speaking patients will not be required to complete patient reported outcomes.

Exclusion Criteria:

• Previous treatment with a SHP2 inhibitor.
• Documented PTPN11 mutations.
• Is currently receiving another treatment within 4 weeks of the first dose of ERAS-601 that may impact the outcome of this trial.
• Patients with prior antineoplastic therapy within \<21 days or 5 half-lives, whichever is shorter.
• Received radiation within 14 days of Cycle 1, Day 1.
• Received strong inhibitors or inducers of CYP3A4, including grapefruit, grapefruit juice, and herbal supplements from 7 days prior to the administration of study drug.
• History of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic soft tissue calcification.
• Gastrointestinal dysfunction that may affect drug absorption.
• Have an untreated, uncontrolled, active infection (bacterial, fungal, or viral) requiring treatment that will impact this protocol.
• History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO.
• Sight-limiting degenerative corneal opacity.
• Have any underlying medical condition (e.g. cardiac, pulmonary, hepatic, etc.), psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise patient safety and/or efficacy evaluation as per protocol.
• Incomplete recovery or ongoing complications from prior surgery that in the opinion of the principal investigator will compromise safety of patient and/or efficacy evaluation of protocol.
• Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study therapy.
• Have a second malignancy that is active and in the opinion of the principal investigator will compromise safety of patient and/or efficacy evaluation of protocol.